Scientific Assistant, Analytical Development & Qc

Job description:

We are at the centre of the rapidly growing cell and gene therapy sector. We deliver life-changing therapies to patients, and so can you.

 

We are currently recruiting for a Scientific Assistant to join the Analytical Development & QC team.  The purpose of this role is to provide essential laboratory activities and services to support the Group.

 

Our Analytical Development and QC Group supports the development of products through analytical testing to facilitate manufacturing and process development, ensuring appropriate quality controls and use of analytics.

 

Your responsibilities in this role would be:

 

• The monitoring and controlling of temperature units within highly regulated laboratories.
• To liaise and work with Equipment Engineering team and external engineers to organize equipment servicing and equipment repair
• Provide support for equipment maintenance including equipment files and service contracts.
• To clean and maintain the laboratory equipment and facilities.
• To operate an autoclave and dispose of waste materials. 
• Support the ASG pipette clinic including cleaning and preparing pipettes.
• Oversee, maintain, and ensure quality of key stock consumables.
• Completing of Quality Records.

Profile description:

We are looking for:

 

• Educated to a minimum of GCSE or equivalent qualification level or able to demonstrate required skills gained within another workplace.
• A genuine interest and drive to work in science.
• Good interpersonal and communication skills (written and verbal)
• Highly organised and motivated with excellent attention to detail.
• Knowledge of MS Office, Word, Excel & Outlook.

 

*Please note this is not considered an undergraduate Scientist opportunity at Oxford Biomedica.  Please see Scientist II or Biotechnologist or other similar opportunities on our career site for these types of roles.

 

 

About Us:

 

Oxford Biomedica is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, we have more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.

 

Oxford Biomedica collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods, and depth of regulatory expertise.

 

What’s in it for you:

 

• Highly competitive reward packages
• Wellbeing programmes
• Development opportunities
• Welcoming, friendly, supportive colleagues
• A diverse and inclusive working environment
• Our values are: Deliver Innovation, Be Inspiring and Have Integrity
• State of the art laboratory and manufacturing facilities

 

We want you to feel inspired every day. We’re future-focused and our business is growing rapidly. We succeed together through passion, commitment and teamwork, and so can you.

 

Collaborate. Contribute. Change lives

We offer:

Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies.  

 

Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy).  

 

Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.